PortalPublikationenExceedingly small iron oxide nanoparticles as positive MRI c...

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Standard

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. / Wei, He; Bruns, Oliver T; Kaul, Michael G; Hansen, Eric C; Barch, Mariya; Wiśniowska, Agata; Chen, Ou; Chen, Yue; Li, Nan; Okada, Satoshi; Cordero, Jose M; Heine, Markus; Farrar, Christian T; Montana, Daniel M; Adam, Gerhard; Ittrich, Harald; Jasanoff, Alan; Nielsen, Peter; Bawendi, Moungi G.

in: P NATL ACAD SCI USA, Jahrgang 114, Nr. 9, 28.02.2017, S. 2325-2330.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wei, H, Bruns, OT, Kaul, MG, Hansen, EC, Barch, M, Wiśniowska, A, Chen, O, Chen, Y, Li, N, Okada, S, Cordero, JM, Heine, M, Farrar, CT, Montana, DM, Adam, G, Ittrich, H, Jasanoff, A, Nielsen, P & Bawendi, MG 2017, 'Exceedingly small iron oxide nanoparticles as positive MRI contrast agents', P NATL ACAD SCI USA, Jg. 114, Nr. 9, S. 2325-2330. https://doi.org/10.1073/pnas.1620145114

APA

Wei, H., Bruns, O. T., Kaul, M. G., Hansen, E. C., Barch, M., Wiśniowska, A., Chen, O., Chen, Y., Li, N., Okada, S., Cordero, J. M., Heine, M., Farrar, C. T., Montana, D. M., Adam, G., Ittrich, H., Jasanoff, A., Nielsen, P., & Bawendi, M. G. (2017). Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. P NATL ACAD SCI USA, 114(9), 2325-2330. https://doi.org/10.1073/pnas.1620145114

Vancouver

Wei H, Bruns OT, Kaul MG, Hansen EC, Barch M, Wiśniowska A et al. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. P NATL ACAD SCI USA. 2017 Feb 28;114(9):2325-2330. https://doi.org/10.1073/pnas.1620145114

Bibtex

@article{9b4f63671ca24cf492313f4c1c4ab519,
title = "Exceedingly small iron oxide nanoparticles as positive MRI contrast agents",
abstract = "Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast. In addition, Gd deposition in the human brain has been reported following contrast, and this is now under investigation by the US Food and Drug Administration (FDA). To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging properties comparable to GBCAs, we have designed and developed zwitterion-coated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) consisting of ∼3-nm inorganic cores and ∼1-nm ultrathin hydrophilic shell. These ZES-SPIONs are free of Gd and show a high T1 contrast power. We demonstrate the potential of ZES-SPIONs in preclinical MRI and magnetic resonance angiography.",
keywords = "Journal Article",
author = "He Wei and Bruns, {Oliver T} and Kaul, {Michael G} and Hansen, {Eric C} and Mariya Barch and Agata Wi{\'s}niowska and Ou Chen and Yue Chen and Nan Li and Satoshi Okada and Cordero, {Jose M} and Markus Heine and Farrar, {Christian T} and Montana, {Daniel M} and Gerhard Adam and Harald Ittrich and Alan Jasanoff and Peter Nielsen and Bawendi, {Moungi G}",
year = "2017",
month = feb,
day = "28",
doi = "10.1073/pnas.1620145114",
language = "English",
volume = "114",
pages = "2325--2330",
journal = "P NATL ACAD SCI USA",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "9",

}

RIS

TY - JOUR

T1 - Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

AU - Wei, He

AU - Bruns, Oliver T

AU - Kaul, Michael G

AU - Hansen, Eric C

AU - Barch, Mariya

AU - Wiśniowska, Agata

AU - Chen, Ou

AU - Chen, Yue

AU - Li, Nan

AU - Okada, Satoshi

AU - Cordero, Jose M

AU - Heine, Markus

AU - Farrar, Christian T

AU - Montana, Daniel M

AU - Adam, Gerhard

AU - Ittrich, Harald

AU - Jasanoff, Alan

AU - Nielsen, Peter

AU - Bawendi, Moungi G

PY - 2017/2/28

Y1 - 2017/2/28

N2 - Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast. In addition, Gd deposition in the human brain has been reported following contrast, and this is now under investigation by the US Food and Drug Administration (FDA). To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging properties comparable to GBCAs, we have designed and developed zwitterion-coated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) consisting of ∼3-nm inorganic cores and ∼1-nm ultrathin hydrophilic shell. These ZES-SPIONs are free of Gd and show a high T1 contrast power. We demonstrate the potential of ZES-SPIONs in preclinical MRI and magnetic resonance angiography.

AB - Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast. In addition, Gd deposition in the human brain has been reported following contrast, and this is now under investigation by the US Food and Drug Administration (FDA). To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging properties comparable to GBCAs, we have designed and developed zwitterion-coated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) consisting of ∼3-nm inorganic cores and ∼1-nm ultrathin hydrophilic shell. These ZES-SPIONs are free of Gd and show a high T1 contrast power. We demonstrate the potential of ZES-SPIONs in preclinical MRI and magnetic resonance angiography.

KW - Journal Article

U2 - 10.1073/pnas.1620145114

DO - 10.1073/pnas.1620145114

M3 - SCORING: Journal article

C2 - 28193901

VL - 114

SP - 2325

EP - 2330

JO - P NATL ACAD SCI USA

JF - P NATL ACAD SCI USA

SN - 0027-8424

IS - 9

ER -